Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 683-690

  Valenti, Luca ^a   Dongiovanni, Paola ^a   Motta, Benedetta Maria ^a   Swinkels, Dorine W ^b   Bonara, Paola ^a   Rametta, Raffaela ^a   Burdick, Larry ^a   Frugoni, Cecelia ^a   Fracanzani, Anna Ludovica ^a   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

atherosclerosis; cytokines; free radicals free radical scavengers; iron; macrophages; risk factors

Indexed keywords

CD36 ANTIGEN; FERRIC AMMONIUM CITRATE; HEMOJUVELIN; HEPCIDIN; HEPCIDIN 25; INTERLEUKIN 6; IRON; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HYPERFERRITINEMIA; MACROPHAGE; MALE; METABOLIC SYNDROME X; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; CAROTID ARTERY DISEASES; CELLS, CULTURED; CHEMOKINE CCL2; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; IRON; IRON METABOLISM DISORDERS; MACROPHAGES; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; QUATERNARY AMMONIUM COMPOUNDS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 79952191602     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.214858     Document Type: Article

References (49)

1. Lapenna D, Pierdomenico SD, Ciofani G, Ucchino S, Neri M, Giamberardino MA, Cuccurullo F. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic Biol Med. 2007;42:492-498. (Pubitemid 46162117)
2. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, Szentmiklosi J, Mehes G, Csonka T, Smith A, Vercellotti GM, Balla G, Balla J. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol. 2010;30:1347-1353.
3. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007;232:1014-1020. (Pubitemid 47358184)
4. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008;172:738-747. (Pubitemid 351354546)
5. Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Messa PG, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol. 2007;27:101-107. (Pubitemid 46364547)
6. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804. (Pubitemid 32550067)
7. Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism. 2005;54:453-459. (Pubitemid 40410444)
8. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, Fay WP. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107: 2601-2606. (Pubitemid 36628943)
9. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999;99: 1222-1229.
10. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998;148:445-451. (Pubitemid 28411101)
11. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297:603-610.
12. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330:1119-1124. (Pubitemid 24118269)
13. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139:704-712. (Pubitemid 24121279)
14. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007;46:1291-1301. (Pubitemid 350144793)
15. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306: 2090-2093. (Pubitemid 40007660)
16. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul MC, Huet PM, Sadoul JL, Gugenheim J, Srai SK, Tran A, Le Marchand-Brustel Y. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology. 2006;131: 788-796. (Pubitemid 44316823)
17. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, Zoller H, Bellmann-Weiler R, Niederegger H, Talasz H, Weiss G. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392-2399. (Pubitemid 351451452)
18. van der AD, Peeters PH, Grobbee DE, Roest M, Marx JJ, Voorbij HM, van der Schouw YT. HFE mutations and risk of coronary heart disease in middle-aged women. Eur J Clin Invest. 2006;36:682-690. (Pubitemid 44393926)
19. Pirart J, Barbier P. Protective effects of hemochromatosis against senile and diabetic angiopathies. Diabetologia. 1971;7:227-236.
20. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268-1273. (Pubitemid 29440117)
21. Pardo Silva MC, Njajou OT, Alizadeh BZ, Hofman A, Witteman JC, van Duijn CM, Janssens AC. HFE gene mutations increase the risk of coronary heart disease in women. Eur J Epidemiol. 2010;25:643-649.
22. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Fargion S, Fracanzani A. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc. In press.
23. Yuan XM, Li W, Baird SK, Carlsson M, Melefors O. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free Radic Res. 2004;38:1133-1142. (Pubitemid 39504349)
24. Engberink MF, Povel CM, Durga J, Swinkels DW, de Kort WL, Schouten EG, Verhoef P, Geleijnse JM. Hemochromatosis (HFE) genotype and atherosclerosis: increased susceptibility to iron-induced vascular damage in C282Y carriers? Atherosclerosis. 2010;211:520-525.
25. Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010;235:633-641.
26. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007;102:1251-1258. (Pubitemid 46802029)
27. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72-78.
28. Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. HFE mutations in nonalcoholic fatty liver disease. Hepatology. 2008;47:1794-1795. (Pubitemid 351702767)
29. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-1778. (Pubitemid 40570925)
30. Valenti L, Fracanzani A, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138: 905-912.
31. Cairo G, Recalcati S, Montosi G, Castrusini E, Conte D, Pietrangelo A. Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. Blood. 1997;89:2546-2553. (Pubitemid 27143304)
32. Kroot J, Laarakkers C, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HPE, van Dongen-Lases E, Wetzels JFM, Sweep FCGJ, Tjalsma H, Swinkels DW. Immunochemical and mass spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56:1570-1579.
33. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood. 2001;97:3707-3712.
34. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, Mattioli M, Levi S, Fiorelli G, Fargion S. Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. Br J Haematol. 2000;110:978-984.
35. Recalcati S, Alberghini A, Campanella A, Gianelli U, De Camilli E, Conte D, Cairo G. Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica. 2006;91:303-310.
36. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1786-1795. (Pubitemid 41243444)
37. Munsaka SM, Agsalda M, Troelstrup D, Hu N, Yu Q, Shiramizu B. Characteristics of activated monocyte phenotype support R5-tropic human immunodeficiency virus. Immunol Immunogenet Insights. 2009; 1:15-20.
38. Garuti C, Tian Y, Montosi G, Sabelli M, Corradini E, Graf R, Ventura P, Vegetti A, Clavien PA, Pietrangelo A. Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation. Gastroenterology. 2010;139:315-322.
39. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008;181:2723-2731.
40. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294. (Pubitemid 11111356)
41. Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand KG, Smith A. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol. 2009;9:109-118.
42. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003;23:1255-1261. (Pubitemid 36871282)
43. Amasyali B, Kose S, Kursaklioglu H, Barcin C, Kilic A. Monocyte chemoattractant protein-1 in acute coronary syndromes: complex vicious interaction. Int J Cardiol. 2009;136:356-357.
44. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88:1121-1127.
45. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2: 275-281. (Pubitemid 128373654)
46. Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int. 2005;68:1533-1542. (Pubitemid 43173381)
47. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006;69:1259-1263.
48. Swinkels DW, Kartikasari AER, van Sante S, van Dijk BA, Muckenthaler M. Hepcidin enhances monocyte activation involved in atherosclerotic vascular disease. Presented at the European Iron Club, September 18-19, 2008, St Gallen, Switzerland.
49. Lawless MW, White M, Mankan AK, O'Dwyer MJ, Norris S. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis. Tissue Antigens. 2007; 70:294-300. (Pubitemid 47340724)